BRPI0417341A - fator ix glicopeguilado - Google Patents

fator ix glicopeguilado

Info

Publication number
BRPI0417341A
BRPI0417341A BRPI0417341-4A BRPI0417341A BRPI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A
Authority
BR
Brazil
Prior art keywords
conjugates
factor
glycosyltransferase
peptide
methods
Prior art date
Application number
BRPI0417341-4A
Other languages
English (en)
Inventor
Shawn De Frees
Robert J Bayer
Caryn Bowe
Krishnasamy Panneerselvam
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of BRPI0417341A publication Critical patent/BRPI0417341A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FATOR IX GLICOPEGUILADO". A presente invenção proporciona conjugados entre o Fator IX e porções de PEG. Os conjugados são ligados via um grupo de ligação de glicosila intacto interposto entre e covalentemente ligado ao peptídeo e ao grupo de modificação. Os conjugados são formados a partir de peptídeos glicosilados através da ação de uma glicosiltransferase. A glicosiltransferase liga uma porção açúcar modificada a um resíduo de glicosila sobre o peptídeo. Também proporcionados são métodos para o preparo dos conjugados, métodos para o tratamento de várias condições de doença com os conjugados e formulações farmacêuticas incluindo os conjugados.
BRPI0417341-4A 2003-12-03 2004-12-03 fator ix glicopeguilado BRPI0417341A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US53938704P 2004-01-26 2004-01-26
US59274404P 2004-07-29 2004-07-29
US61451804P 2004-09-29 2004-09-29
US62338704P 2004-10-29 2004-10-29
PCT/US2004/041070 WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Publications (1)

Publication Number Publication Date
BRPI0417341A true BRPI0417341A (pt) 2007-04-17

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417341-4A BRPI0417341A (pt) 2003-12-03 2004-12-03 fator ix glicopeguilado

Country Status (10)

Country Link
EP (1) EP1694315A4 (pt)
JP (1) JP4738346B2 (pt)
KR (1) KR101209111B1 (pt)
AU (1) AU2004296860B2 (pt)
BR (1) BRPI0417341A (pt)
CA (1) CA2549413A1 (pt)
IL (1) IL175661A0 (pt)
MX (1) MXPA06006023A (pt)
NZ (1) NZ546733A (pt)
WO (1) WO2005055950A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
ES2420581T3 (es) 2003-03-14 2013-08-26 Biogenerix Gmbh Polímeros solubles en agua ramificados y sus conjugados
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2009515508A (ja) * 2005-08-19 2009-04-16 ネオス テクノロジーズ インコーポレイテッド グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
SI2068907T1 (en) * 2006-10-04 2018-01-31 Novo Nordisk A/S Pegylated sugars and glycopeptides are associated with glycerol
CN105838699A (zh) 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20110154516A1 (en) * 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
NZ598193A (en) * 2007-12-27 2012-12-21 Baxter Int Chemically Modified Factor IX
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
CA2721683A1 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
EP2461821A4 (en) * 2009-07-31 2013-07-03 Bayer Healthcare Llc MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
SG191298A1 (en) 2010-12-22 2013-07-31 Baxter Int Materials and methods for conjugating a water soluble fatty acid derivative to a protein
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
AU2020242945A1 (en) 2019-03-19 2021-10-14 CSL Innovation Pty Ltd Factor IX variants and uses thereof in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
MXPA00005376A (es) * 1997-12-01 2002-07-02 Neose Technologies Inc Sintesis enzimatica de gangliosidos.
ES2516041T3 (es) * 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)

Also Published As

Publication number Publication date
KR20060123224A (ko) 2006-12-01
JP4738346B2 (ja) 2011-08-03
AU2004296860A1 (en) 2005-06-23
NZ546733A (en) 2009-07-31
IL175661A0 (en) 2006-09-05
AU2004296860B2 (en) 2010-04-22
EP1694315A4 (en) 2009-10-28
WO2005055950A2 (en) 2005-06-23
JP2007513190A (ja) 2007-05-24
EP1694315A2 (en) 2006-08-30
CA2549413A1 (en) 2005-06-23
KR101209111B1 (ko) 2012-12-06
WO2005055950A3 (en) 2005-10-20
MXPA06006023A (es) 2006-08-23

Similar Documents

Publication Publication Date Title
BRPI0417341A (pt) fator ix glicopeguilado
BRPI0417342A (pt) fator estimulante de colÈnia de granulócitos glicopeguilado
BRPI0614839A2 (pt) fator vii e fator viia glicopeguilados
Zanini et al. Novel Dendritic α-Sialosides: Synthesis of Glycodendrimers Based on a 3, 3 ‘-Iminobis (propylamine) Core
WO2005051327A3 (en) Glycopegylated erythropoietin
Schroeder et al. The disaccharide moiety of bleomycin facilitates uptake by cancer cells
FI93227C (fi) Hiilihydraattiyhdisteen käyttö in vitro viruspartikkelien tai viruksen pintakomponenttien valmistukseen tai eristämiseen
Bonduelle et al. Synthetic glycopolypeptides as biomimetic analogues of natural glycoproteins
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
WO2006127896A3 (en) Glycopegylated factor ix
ES2699312T3 (es) Enlace covalente reversible de moléculas funcionales
AU729643B2 (en) Polypeptide conjugates for transporting substances across cell membranes
US6030941A (en) Polymer composition for delivering substances in living organisms
WO2006031811A3 (en) Glycopegylated interferon alpha
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
BR9814276A (pt) Antìgenos de superfìcie
YU48703A (sh) Novi interferonu beta-slični molekuli
ATE369878T1 (de) Träger-pharmaka-konjugate
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
Shin et al. Chemoselective ligation of maleimidosugars to peptides/protein for the preparation of neoglycopeptides/neoglycoprotein
US11730786B2 (en) High molecular weight polysaccharide that binds and inhibits virus
Johansson et al. Multivalent HSA conjugates of 3′‐sialyllactose are potent inhibitors of adenoviral cell attachment and infection

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK A/S (DK)

Free format text: TRANSFERIDO DE: NEOSE TECHNOLOGIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B10A Cessation: cessation confirmed